Parnaparin sodium: Difference between revisions
Content deleted Content added
Updating {{drugbox}} (no changed fields - updated 'ChemSpiderID_Ref', 'DrugBank_Ref', 'UNII_Ref', 'ChEMBL_Ref', 'ChEBI_Ref', 'KEGG_Ref', 'StdInChI_Ref', 'StdInChIKey_Ref', 'ChEBI_Ref') per Chem/Drugbox validation (report [[Wikipedia |
Citation bot (talk | contribs) Add: s2cid. | Use this bot. Report bugs. | Suggested by Spinixster | Category:Blood and blood forming organ drug stubs | #UCB_Category 48/94 |
||
| (15 intermediate revisions by 13 users not shown) | |||
| Line 1: | Line 1: | ||
{{Short description|Pharmaceutical drug}} |
|||
{{Drugbox |
{{Drugbox |
||
| verifiedrevid = |
| verifiedrevid = 447910030 |
||
| IUPAC_name = |
| IUPAC_name = |
||
| image = |
| image = File:Heparin General Structure V.1.svg |
||
| ⚫ | |||
| ⚫ | |||
| tradename = |
| tradename = |
||
| Drugs.com = {{drugs.com|international|parnaparin-sodium}} |
| Drugs.com = {{drugs.com|international|parnaparin-sodium}} |
||
| Line 14: | Line 14: | ||
| legal_UK = <!-- GSL / P / POM / CD / Class A, B, C --> |
| legal_UK = <!-- GSL / P / POM / CD / Class A, B, C --> |
||
| legal_US = <!-- OTC / Rx-only / Schedule I, II, III, IV, V --> |
| legal_US = <!-- OTC / Rx-only / Schedule I, II, III, IV, V --> |
||
| legal_status = |
| legal_status = |
||
| routes_of_administration = |
| routes_of_administration = |
||
| ⚫ | |||
| bioavailability = |
|||
| ⚫ | |||
| |
| protein_bound = |
||
| |
| metabolism = |
||
| ⚫ | |||
| metabolism = |
|||
| ⚫ | |||
| excretion = |
| excretion = |
||
| ⚫ | |||
| CAS_number_Ref = {{cascite|correct|CAS}} |
|||
| ⚫ | |||
| CAS_number = |
| CAS_number = 9041-08-1 |
||
| ATC_prefix = B01 |
| ATC_prefix = B01 |
||
| ATC_suffix = AB07 |
| ATC_suffix = AB07 |
||
| PubChem = |
| PubChem = |
||
| DrugBank_Ref = {{drugbankcite|correct|drugbank}} |
| DrugBank_Ref = {{drugbankcite|correct|drugbank}} |
||
| DrugBank = |
| DrugBank = DB09260 |
||
| ChemSpiderID = none |
|||
| KEGG = D04977 |
|||
| ⚫ | |||
| UNII = U6K360XMIU |
|||
| chemical_formula = |
|||
| ⚫ | |||
| |
| chemical_formula = |
||
| molecular_weight = |
|||
}} |
}} |
||
'''Parnaparin''' is an [[antithrombotic]] and belongs to the group of [[low molecular weight heparin]]s. In the prevention and therapy of thromboembolic pathologies, the advent of this class of drugs represented a medical development, since they retain the same effectiveness of unfractionated heparin but with simpler dosing regimens and decreased side effects. In addition to being effective in treating proven deep vein thrombosis and thrombosis-associated phlebopathies, Parnaparin has demonstrated its thromboprophylactic efficacy in both high- and moderate-risk surgical patients. |
|||
'''Parnaparin''' is an antithrombotic in the [[heparin]] group. |
|||
==External links== |
==External links== |
||
* {{MeshName|parnaparin}} |
* {{MeshName|parnaparin}} |
||
* {{cite journal | |
* {{cite journal |vauthors=Maugeri N, Di Fabio G, Barbanti M, de Gaetano G, Donati MB, Cerletti C |title=Parnaparin, a low-molecular-weight heparin, prevents P-selectin-dependent formation of platelet-leukocyte aggregates in human whole blood |journal=Thromb. Haemost. |volume=97 |issue=6 |pages=965–73 |year=2007 |pmid=17549299 |doi=10.1160/th06-12-0680|s2cid=24068001 }} |
||
{{Antithrombotics}} |
{{Antithrombotics}} |
||
| Line 49: | Line 49: | ||
{{blood-drug-stub}} |
{{blood-drug-stub}} |
||
[[pt:Parnaparina sódica]] |
|||